Thomas Edward Hamilton is Director at Larimar Therapeutics, Inc. (LRMR). They have made 8 open-market trades across 2 companies since 2019, most recently 2026-07-06.
CIK 0001769848
7 open-market purchases totalling $5.1M since 2019, against 1 sale. Across 7 scored buys the stock is down 0.1% at ninety days, and 5.4 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| NLY | 330,000 | $6.0M |
| LRMR | 714,798 | $1.4M |
| Total | $7.4M |
Shares reported on the most recent Form 4, priced at the 2026-07-08 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 29% | 29% | 43% |
| Avg Move | -2.5% | -1.7% | -0.1% |
| Alpha | -1.4% | -2.6% | -5.4% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LRMR | BUY | 2026-07-06 | 2026-07-08 | $3.34 | $167K | -1.3% | +7.2% | -28.2% |
| LRMR | BUY | 2026-02-27 | 2026-03-02 | $5.00 | $500K | -14.5% | -16.3% | -36.9% |
| LRMR | BUY | 2024-02-16 | 2024-05-31 | $8.74 | $1000K | +13.4% | -2.8% | -5.1% |
| LRMR | BUY | 2022-09-16 | 2022-09-20 | $3.15 | $1000K | -7.0% | -3.2% | +46.8% |
| LRMR | BUY | 2021-06-30 | 2021-07-02 | $8.75 | $992K | -7.4% | -10.4% | +2.6% |
| NLY | SELL | 2021-05-03 | 2021-05-04 | $9.18 | $734K | +1.0% | +4.2% | -6.9% |
| NLY | BUY | 2020-05-15 | 2020-05-15 | $5.96 | $1.2M | +4.4% | +14.7% | +22.9% |
| NLY | BUY | 2019-05-17 | 2019-05-20 | $9.47 | $284K | -5.3% | -1.0% | -3.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.